Expanded Access Use of Ladiratuzumab Vedotin in Advanced Solid Tumors
NCT06362590 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-06-17
Summary
The purpose of this study is to provide the option of Ladiratuzumab Vedotin treatment to eligible patients in studies SGNLVA-005.
Interventions
- DRUG
-
ladiratuzumab vedotin
Sponsors & Collaborators
-
Seagen Inc.
lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of SGN-ALPV in Advanced Solid Tumors
NCT05229900 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT04106492 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors
NCT03700294 ·Status: TERMINATED ·Phase: PHASE1
-
Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
NCT07192432 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Safety Study of SGN-CD47M in Patients With Solid Tumors
NCT03957096 ·Status: TERMINATED ·Phase: PHASE1
-
Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors
NCT03474289 ·Status: UNKNOWN ·Phase: PHASE1
-
Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors
NCT03364400 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors
NCT06710379 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors
NCT05701709 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
NCT05901285 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors
NCT02759666 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer
NCT06163391 ·Status: RECRUITING ·Phase: PHASE1
-
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
NCT06797362 ·Status: AVAILABLE
-
An Open Label Treatment Extension Study of AMG 706
NCT00360867 ·Status: TERMINATED ·Phase: PHASE2
-
Continuing Access to Axitinib (A406- AG- 013736 ) For Patients Previously Receiving AG 013736 In Clinical Trials
NCT00828919 ·Status: COMPLETED ·Phase: NA
-
Exceptional Responders With Solid Tumor Cancer to Chemotherapy
NCT02555735 ·Status: ENROLLING_BY_INVITATION
-
A Study of mRNA-4106 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Solid Tumors
NCT06880549 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
An Extension Study of ABT-806 in Subjects With Advanced Solid Tumors
NCT01406119 ·Status: COMPLETED ·Phase: PHASE1
-
Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
NCT00629200 ·Status: COMPLETED ·Phase: PHASE1
-
AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification
NCT03253679 ·Status: COMPLETED ·Phase: PHASE2
-
First in Human Study of M1069 in Advanced Solid Tumors
NCT05198349 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies
NCT03834662 ·Status: COMPLETED ·Phase: PHASE1
-
Study of VG2025 Delivered Intraperitoneally in Patients With Advanced Solid Tumors With Carcinomatosis
NCT06365918 ·Status: WITHDRAWN ·Phase: PHASE1
-
Extended Use Protocol for Participants With Cancer to Receive Continued Treatment With CS-7017
NCT00881569 ·Status: COMPLETED ·Phase: PHASE1